Rafael Bárcena Marugán-rekin lankidetzan egindako argitalpenak (21)

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2012

  1. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.

    Journal of acquired immune deficiency syndromes (1999)

2011

  1. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia

    Liver Transplantation, Vol. 17, Núm. 3, pp. 331-333

2010

  1. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation

    Liver Transplantation

  2. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage

    AIDS

2009

  1. False-positive results of aspergillus galactomannan antigenemia in liver transplant recipients

    Transplantation, Vol. 87, Núm. 2, pp. 256-260

2008

  1. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation

    AIDS

  2. Severe Sirolimus-Related Inflammatory State Anemia in an HIV+ Liver Transplant Patient With Calcineurin Inhibitor Renal Insufficiency: A Case Report

    Transplantation Proceedings, Vol. 40, Núm. 10, pp. 3810-3812

2007

  1. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1

    Antiviral Therapy, Vol. 12, Núm. 3, pp. 401-406

2006

  1. Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature

    Human Pathology, Vol. 37, Núm. 10, pp. 1344-1349

  2. Viral kinetics and early prediction of nonresponse to peg-IFN-α-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus

    Journal of Viral Hepatitis, Vol. 13, Núm. 7, pp. 466-473

2005

  1. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: An intent to find the optimal cut-off value

    Journal of Clinical Virology, Vol. 33, Núm. 2, pp. 138-144

  2. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-α-2b/ribavirin

    Journal of Hepatology, Vol. 43, Núm. 5, pp. 783-790

  3. Liver transplantation in HIV-infected recipients

    Liver Transplantation, Vol. 11, Núm. 1, pp. 76-81

  4. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization

    European Journal of Gastroenterology and Hepatology, Vol. 17, Núm. 11, pp. 1157-1164

2004

  1. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin

    Antiviral Therapy, Vol. 9, Núm. 1, pp. 133-138

  2. Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin

    Antiviral Therapy, Vol. 9, Núm. 6, pp. 1027-1030

  3. Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 18, Núm. 1, pp. 67-73

2003

  1. Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 813-819

2002

  1. Prophylaxis with oral fluconazole and an oral solution of amphotericin B in liver transplant patients

    Transplantation Proceedings, Vol. 34, Núm. 1, pp. 80-81